FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2281899782> ?p ?o ?g. }

• W2281899782 endingPage "2004" @default.
• W2281899782 startingPage "1999" @default.
• W2281899782 abstract "Abstract Antiprothrombin and anti–β2-glycoprotein I (β2-GPI) antibodies belong to the family of antiphospholipid (APL) antibodies and represent the phospholipid-dependent inhibitors of coagulation. They may be distinguished by analyzing the coagulation profiles generated by the comparison of the ratios of two coagulation tests, the Kaolin Clotting Time (KCT) and the dilute Russell's Viper Venom Time (dRVVT), commonly adopted for their diagnosis. The KCT profile is caused by antiprothrombin antibodies, whereas anti–β2-GPI antibodies are responsible for the dRVVT coagulation profile. The presence of aPL antibodies is frequently associated with acquired resistance to activated Protein C (APC-R), but limited information is available regarding the role of the different antibodies in its development. We studied the time-course of activated Factor V (FVa) generation and inactivation in the plasma of 42 patients with well-defined phospholipid-dependent inhibitors of coagulation: 24 displayed the dRVVT coagulation profile, whereas the other 18 cases showed the KCT profile. In normal pooled plasma, the peak values of FVa (mean ± standard deviation, [SD]: 16.307 ± 4.372 U/mL) were reached in 4 to 5 minutes and an almost complete inactivation (0.088 ± 0.123 U/mL) was obtained within 20 minutes. At this time point, values of residual FVa exceeding 2 SD the mean of controls (0.344 U/mL) were considered abnormal. Patients belonging to the KCT coagulation profile group reached the maximal amount of FVa in plasma (22.740 ± 7.693 U/mL, P = not significant v controls) within 4 to 5 minutes; at 20 minutes, the residual amount of FVa in plasma ranged from 0 to 1.09 U/mL (0.293 ± 0.298; P = .027), but it was found abnormal in only six of the 18 cases. The time-course of FVa in plasma of patients belonging to the dRVVT coagulation profile group differed from that of normal controls in that the peak values (10.955 ± 5.092 U/mL) were reached at 10 minutes and the amount of residual FVa at 20 minutes ranged from 0.320 to 14.450 U/ml (2.544 ± 3.580 U/mL;P = .0191 v normal controls and P = .0114v KCT group patients). Twenty of the 24 patients belonging to the dRVVT profile group had an abnormal inactivation of FVa (χ2 = 0.001 v KCT group patients). History of venous thrombosis was experienced by 15 patients: an abnormal rate of FVa inactivation was found in 11 of them (73%) versus 15 of the 27 cases without thrombosis (56%) (x2= 0.2556). The effect of affinity-purified IgG phospholipid-dependent inhibitors of coagulation on the time-course of FVa generation and inactivation in normal plasma was also investigated. Anti–β2-GPI, but not antiprothrombin antibodies, hampered the inactivation of FVa by endogenous APC, thus reproducing the behavior of the original plasmas. This effect was strictly β2-GPI–dependent. In conclusion, our findings confirm that anti–β2-GPI antibodies identify patients with phospholipid-dependent inhibitors of coagulation at increased risk of thrombosis and suggest acquired APC-R as a possible explanation of the pathogenesis of the thromboembolic events." @default.
• W2281899782 created "2016-06-24" @default.
• W2281899782 creator A5011382851 @default.
• W2281899782 creator A5069072959 @default.
• W2281899782 creator A5079910766 @default.
• W2281899782 date "1998-03-15" @default.
• W2281899782 modified "2023-09-30" @default.
• W2281899782 title "Differential Effects of Anti–β2-Glycoprotein I and Antiprothrombin Antibodies on the Anticoagulant Activity of Activated Protein C" @default.
• W2281899782 cites W1482317494 @default.
• W2281899782 cites W1812735750 @default.
• W2281899782 cites W1991153412 @default.
• W2281899782 cites W2007914723 @default.
• W2281899782 cites W2017528387 @default.
• W2281899782 cites W2017687893 @default.
• W2281899782 cites W2021306080 @default.
• W2281899782 cites W2022510326 @default.
• W2281899782 cites W2031534496 @default.
• W2281899782 cites W2034787765 @default.
• W2281899782 cites W2041297457 @default.
• W2281899782 cites W2076944027 @default.
• W2281899782 cites W2101831374 @default.
• W2281899782 cites W2113891001 @default.
• W2281899782 cites W2409945121 @default.
• W2281899782 cites W2415371444 @default.
• W2281899782 cites W2437357051 @default.
• W2281899782 cites W4296981399 @default.
• W2281899782 cites W4298354788 @default.
• W2281899782 cites W458440 @default.
• W2281899782 doi "https://doi.org/10.1182/blood.v91.6.1999" @default.
• W2281899782 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9490682" @default.
• W2281899782 hasPublicationYear "1998" @default.
• W2281899782 type Work @default.
• W2281899782 sameAs 2281899782 @default.
• W2281899782 citedByCount "111" @default.
• W2281899782 countsByYear W22818997822012 @default.
• W2281899782 countsByYear W22818997822013 @default.
• W2281899782 countsByYear W22818997822014 @default.
• W2281899782 countsByYear W22818997822015 @default.
• W2281899782 countsByYear W22818997822016 @default.
• W2281899782 countsByYear W22818997822017 @default.
• W2281899782 countsByYear W22818997822019 @default.
• W2281899782 countsByYear W22818997822021 @default.
• W2281899782 countsByYear W22818997822022 @default.
• W2281899782 crossrefType "journal-article" @default.
• W2281899782 hasAuthorship W2281899782A5011382851 @default.
• W2281899782 hasAuthorship W2281899782A5069072959 @default.
• W2281899782 hasAuthorship W2281899782A5079910766 @default.
• W2281899782 hasBestOaLocation W22818997821 @default.
• W2281899782 hasConcept C126322002 @default.
• W2281899782 hasConcept C159654299 @default.
• W2281899782 hasConcept C185592680 @default.
• W2281899782 hasConcept C203014093 @default.
• W2281899782 hasConcept C2776046644 @default.
• W2281899782 hasConcept C2778382381 @default.
• W2281899782 hasConcept C2780868729 @default.
• W2281899782 hasConcept C2781287897 @default.
• W2281899782 hasConcept C71924100 @default.
• W2281899782 hasConcept C77171857 @default.
• W2281899782 hasConceptScore W2281899782C126322002 @default.
• W2281899782 hasConceptScore W2281899782C159654299 @default.
• W2281899782 hasConceptScore W2281899782C185592680 @default.
• W2281899782 hasConceptScore W2281899782C203014093 @default.
• W2281899782 hasConceptScore W2281899782C2776046644 @default.
• W2281899782 hasConceptScore W2281899782C2778382381 @default.
• W2281899782 hasConceptScore W2281899782C2780868729 @default.
• W2281899782 hasConceptScore W2281899782C2781287897 @default.
• W2281899782 hasConceptScore W2281899782C71924100 @default.
• W2281899782 hasConceptScore W2281899782C77171857 @default.
• W2281899782 hasIssue "6" @default.
• W2281899782 hasLocation W22818997821 @default.
• W2281899782 hasOpenAccess W2281899782 @default.
• W2281899782 hasPrimaryLocation W22818997821 @default.
• W2281899782 hasRelatedWork W1970620280 @default.
• W2281899782 hasRelatedWork W1970851316 @default.
• W2281899782 hasRelatedWork W2020657380 @default.
• W2281899782 hasRelatedWork W2027530885 @default.
• W2281899782 hasRelatedWork W2103849581 @default.
• W2281899782 hasRelatedWork W2115885282 @default.
• W2281899782 hasRelatedWork W2380161821 @default.
• W2281899782 hasRelatedWork W2748952813 @default.
• W2281899782 hasRelatedWork W2769424276 @default.
• W2281899782 hasRelatedWork W2899084033 @default.
• W2281899782 hasVolume "91" @default.
• W2281899782 isParatext "false" @default.
• W2281899782 isRetracted "false" @default.
• W2281899782 magId "2281899782" @default.
• W2281899782 workType "article" @default.